NEW YORK, NY / ACCESSWIRE / June 14, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Romeo Power, Inc. (NYSE:RMO)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/romeo-power-inc-loss-submission-form?prid=16846&wire=1
Lead Plaintiff Deadline: June 15, 2021
Class Period: October 5, 2020 - March 30, 2021
Allegations against RMO include that: (i) Romeo had only two battery cell suppliers, not four, (ii) the future potential risks that Defendants warned of concerning supply disruption or shortage had already occurred and were already negatively affecting Romeo's business, operations and business prospects, (iii) Romeo did not have the battery cell inventory to accommodate end-user demand and ramp up production in 2021, (iv) Romeo's supply constraint was a material hindrance to Romeo's revenue growth, and (v) Romeo's supply chain for battery cells was not hedged, but in fact, was totally at risk and beholden to just two battery cell suppliers and the spot market for their 2021 inventory. Given the supply constraint that Romeo was experiencing during the Class Period, Defendants had no reasonable basis to represent that the Company had the ability to meet customer demand and that it would support growth in revenue in 2021.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=16846&wire=1
Lead Plaintiff Deadline: August 2, 2021
Class Period: November 16, 2020 - March 22, 2021
Allegations against FREQ include that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
RLX Technology Inc. (NYSE:RLX)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/rlx-technology-inc-loss-submission-form?prid=16846&wire=1
Lead Plaintiff Deadline: August 9, 2021
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the F-1 registration statement and related prospectus on Form 424B4 issued in connection with RLX's January 2021 initial public stock offering.
Allegations against RLX include that: the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong